Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QT-Cab: An Open-Label Study to Investigate the Effect of Cabazitaxel on the QTc Interval in Cancer Patients

NCT01087021 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01087021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01087021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QT-Cab: An Open-Label Study to Investigate the Effect of Cabazitaxel on the QTc Interval in Cancer Patients
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2010
Completion date
November 30, 2011
Enrollment
45 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, malignant